Who is sponsoring NCT00540631?

NCT00540631 is sponsored by Allergopharma GmbH & Co. KG.

What condition does NCT00540631 study?

NCT00540631 studies Rhinoconjunctivitis.

Is NCT00540631 still recruiting?

NCT00540631 is currently completed. Last updated 8 February 2013.

Last reviewed 2013-02-08 · How we verify

NCT00540631: ACRI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicentre Randomized Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of a Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of House Dust Mite (Dermatophagoides Pteronyssinus) in Patients With Rhinitis/Rhinoconjunctivitis and/or Allergic Asthma Bronchiale

Completed Phase 3 Last updated 8 February 2013

What this trial tests

Phase 3 trial testing specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU) in Rhinoconjunctivitis in 108 participants. Completed in 1 December 2011.

Timeline

1 October 2007

Primary endpoint
1 August 2010

1 December 2011

Quick facts

Lead sponsor	Allergopharma GmbH & Co. KG
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	108
Start date	1 October 2007
Primary completion	1 August 2010
Estimated completion	1 December 2011
Sites	1 location across Germany

Drugs / interventions tested

specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU) — full drug profile →

Conditions studied

Rhinoconjunctivitis — all drugs for Rhinoconjunctivitis →

Sponsor

Allergopharma GmbH & Co. KG — full company profile →

Who can join

Adults 18 to 60, any sex, with Rhinoconjunctivitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The primary endpoint is the change of the area under the curve (AUC)of the Symptom-Medication-Score (SMS)after 2 years of double-blind treatment to baseline
Time frame: November 2007 - February 2010

Sponsor's own description

Multicenter Immunotherapy House Dust Mite Allergoid

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The evidence for commercial house dust mite immunotherapy products: A pragmatic systematic review with narrative synthesis.
West T, Katelaris CH. · · 2024 · cited 3× · PMID 39092213 · DOI 10.1016/j.jacig.2024.100255

Verify or expand the search:

Other Allergopharma GmbH & Co. KG trials

Trials by the same sponsor.

NCT07096440 — Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00540631 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allergopharma GmbH & Co. KG
Last refreshed: 8 February 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00540631.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing